非小细胞肺癌耐药分子指标研究进展  

Research advances in drug resistance markers in non-small cell lung cancer

作　　者：苏琴[1] 彭朝津[1] 

机构地区：[1]解放军第三0四医院老年科，北京100037

出　　处：《中国癌症杂志》2003年第5期472-474,共3页China Oncology

摘　　要：化疗在治疗非小细胞肺癌 (NSCLC)中占有重要地位 ,但其联合化疗的有效率也只有 30 %～ 4 0 % ,并且这个水平已达到了一个新的平台阶段。影响肺癌患者化疗疗效的主要原因是肿瘤细胞对抗癌药的抗药性 ,其耐药机制非常复杂 ,与耐药基因MDR1、MRP、LRP ,GST、拓扑异构酶Ⅱ质和量的改变、β 微管蛋白基因突变、FGF等多种因素有关。前瞻性进行分子指标的测定 ,是指导肺癌患者化疗用药、进行个体化治疗。Chemotherapy is the basic therapy in non small cell lung cancer, but combined chemotherapy has a response rate that still remains in the range of 30%-40%. Resistance of cancer cells to the anti tumor drugs is the main factor that reduces the efficacy of the chemotherapy. The mechanism of the drug resistance of lung cancer cells is very complex involving changes of drug resistance gene MDR1, MRP, LRP,GST, change of quality and quantity of toposomerase Ⅱ, β tubulin gene mutation and fibroblast growth factor. Prospective measurement of the molecular marker as a guide for clinical chemotherapy is a key factor that can facilitate the individualization of the regime and thus increase the response rate.

关 键 词：非小细胞肺癌 耐药基因 分子指标 抗药性 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]